RSS_IDENT_s_31484543_b_1_2_4
 Antibodies The sources of purchased antibodies were as follows: KIT (M− ¹⁴), cathepsin D (H− ⁷⁵), STAT5 (C-17), ERK2 (K-23), ARF1 (ARFS 3F1), GBF1 (25), PTP1B (D-4), SHP-1 (D-11), and SHP-2 (B-1) from Santa Cruz Biotechnology (Dallas, TX); KIT [pY703] (D12E12), KIT (D13A2), LAMP1 (lysosome-associated membrane protein 1, D4O1S), AKT (40D4), AKT [pT308] (C31E5E), STAT5 (D2O6Y), STAT5[pY694] (D47E7), ERK1/2 (137F5) and ERK [pT202/pY204] (E10) from Cell Signaling Technology (Danvers, MA); PDI (RL90), TFR (transferrin receptor, ab84036), giantin (ab24586), and GM130 (EP892Y) from Abcam (Cambridge, UK); TFR (H68.4) from Thermo Fisher Scientific (Rockford, IL); calnexin (ADI-SPA-860) from Enzo (Farmingdale, NY); GM130 (clone 35) from BD Transduction Laboratories (Franklin Lakes, NJ); LAMP1 (L1418) from Sigma (St. Louis, MO) and KIT (104D2) from Biolegend (San Diego, CA). HRP-labeled secondary antibodies were purchased from the Jackson Laboratory (Bar Harbor, MA). Alexa Fluor-conjugated secondary antibodies were obtained from Molecular Probes (Eugene, OR).
